Facts and figures

Headquarters in Denmark
Worldwide: Production facilities in six countries, affiliates or offices in 79 countries
Workforce: 22,460 employees

Novo Nordisk’s workforce is growing outside Denmark: 56% of employees are located in Denmark, 44% in the rest of the world.

15% within research and development
38% in production and production administration
28% in international sales and marketing
19% in administration

Diabetes care
Haemostasis management (NovoSeven®)
Growth hormone therapy
Hormone replacement therapy (HRT)

Sales: 33,760 million Danish kroner (full year 2005)

Diabetes care: 24,012 million Danish kroner
Biopharmaceuticals: 9,748 million Danish kroner
Sales per segment

Sales growth was realised in all regions. The main growth driver was North America, constituting 28% of total sales, followed by International Operations with 18% of total sales.

Europe 12,411 million Danish kroner
Japan & Oceania 4,298 million Danish kroner
North America 7,478 million Danish kroner
International Operations 4,844 million Danish kroner
Sales per region

This page has been assessed by PricewaterhouseCoopers as part of its assessment of Novo Nordisk’s statement that it reports ‘in accordance’ with GRI. Please refer to Audit and assurance for a full description of the nature of assurance offered.